| 145.2385 -7.862 (-5.13%) | 08-28 12:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 181.54 | 1-year : | 212.04 |
| Resists | First : | 155.42 | Second : | 181.54 |
| Pivot price | 134.73  |
|||
| Supports | First : | 109.17 | Second : | 80.58 |
| MAs | MA(5) : | 147.82 |
MA(20) : | 128.06 |
| MA(100) : | 84.24 |
MA(250) : | 55.65 |
|
| MACD | MACD : | 13.6 |
Signal : | 12.1 |
| %K %D | K(14,3) : | 85.5 |
D(3) : | 89.5 |
| RSI | RSI(14): 62.1 |
|||
| 52-week | High : | 155.42 | Low : | 23.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TWST ] has closed below upper band by 31.7%. Bollinger Bands are 96.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 155.57 - 156.33 | 156.33 - 156.98 |
| Low: | 146.67 - 147.52 | 147.52 - 148.26 |
| Close: | 151.8 - 153.15 | 153.15 - 154.3 |
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Thu, 27 Aug 2026
Twist Bioscience(TWST.US) Officer Sells US$6.32 Million in Common Stock - Moomoo
Tue, 25 Aug 2026
Twist Bioscience Corp (TWST) Stock Up 7.5% but GF Value Says Ove - GuruFocus
Tue, 25 Aug 2026
Twist Bioscience (NASDAQ: TWST) COO sells shares in tax-withholding trade - Stock Titan
Tue, 25 Aug 2026
Twist Bioscience (TWST) HR chief’s share sale is tax-driven - Stock Titan
Mon, 24 Aug 2026
Twist Bioscience Corp (TWST) Shares Fall 3.3% -- What GF Score o - GuruFocus
Thu, 20 Aug 2026
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 63 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 115.9 (%) |
| Shares Short | 14,080 (K) |
| Shares Short P.Month | 13,950 (K) |
| EPS | -2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | -31.7 % |
| Operating Margin | -30.7 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -29.6 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 3.57 |
| Sales Per Share | 6.88 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -64.45 |
| PEG Ratio | 0 |
| Price to Book value | 20.21 |
| Price to Sales | 20.87 |
| Price to Cash Flow | -169.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|